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Simple Summary: Sarcoids are skin tumors on horses where better treatment options are needed.
Calcium electroporation is a novel anti-cancer treatment where calcium is injected into the tumor,
followed by brief electric pulses (electroporation) that transiently open the cell membrane and allow
uptake of calcium. This, in turn, induces cell death. In this study, we aimed to investigate the safety
and effect of calcium electroporation on sarcoids. Thirty-two sarcoids in eight horses were treated
once or twice with calcium electroporation and followed for 12–38 weeks with size-measurement and
clinical photographs. The study showed that calcium electroporation is a safe and feasible treatment
for sarcoids, including inoperable sarcoids. Six of 27 sarcoids (22%) were completely eliminated,
and six further sarcoids (22%) decreased more than 30% in size. No relation between response and
location, type, nor size of the sarcoid was observed. Larger studies are needed to further investigate
the effect of calcium electroporation on sarcoids.
Abstract: Sarcoids are common equine skin tumors where the risk of recurrence after treatment is
high, and better treatment options are warranted. Calcium electroporation is a novel anti-cancer
treatment where lethally high calcium concentrations are introduced into the cells by electroporation,
a method where short high-voltage pulses induce transient permeabilization of the cell membrane.
This study investigated the safety and long-term response of calcium electroporation on sarcoids.
Thirty-two sarcoids in eight horses were included. The study suggested that calcium electroporation
is a safe and feasible treatment for sarcoids, including inoperable sarcoids. Horses were treated once
(2/8) or twice (6/8) under general anesthesia, where sarcoids were injected with 220 mM calcium
chloride followed by electroporation with 8 pulses of 100 µs, 1 kV/cm, and 1 Hz. Biopsies were taken
prior to treatment. The sarcoid size was monitored for 12–38 weeks after the first treatment. Complete
response was observed in 22% (6/27) of treated sarcoids, and partial response in 22% (6/27), giving a
44% total response. Treatment efficacy did not appear to be related to location, type, or size. In all
non-biopsied lesions, a complete response was seen (4/4). In conclusion, in this small study, 44% of
sarcoids responded with 22% of sarcoids disappearing.
Keywords: calcium electroporation; sarcoid; equine; horse; response; biopsy
1. Introduction
Sarcoids are the most common equine skin tumors. They are benign tumors of mesenchymal
origin classified as occult, verrucous, nodular, fibroblastic, or mixed, and, in rare cases, malignant.
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Sarcoids may develop in any location but are often found in the head and neck area, as well as the
ventral abdomen. Sarcoids are normally not lethal by themselves; however, the size and distribution
can severely compromise the use and value of the horse and lead to a decision of euthanasia [1,2].
There is no universally effective treatment option for sarcoids where the most frequently used options
are conventional excision, laser treatment, cryotherapy, radiotherapy, and chemotherapy, as well as
antiviral or immune-modulating treatment. There is a high risk of recurrence; thus, investigations in
new therapies are warranted [1,2].
Calcium electroporation is a prospective novel anticancer treatment, showing promising response
rates in preclinical and clinical trials [3–7]. High calcium concentrations are introduced to the cell
cytosol by electroporation, a method where short, high-voltage pulses permeabilize the cell membrane,
allowing for passage of non-permeant ions and molecules, e.g., calcium [4,7]. Calcium is a ubiquitous
second messenger involved in most cellular processes, including cell death, and, therefore, is tightly
regulated by channels, transporters, and intracellular chelators [8]. The high intracellular calcium
concentration induced by calcium electroporation causes ATP depletion, mitochondrial dysfunction,
and cell death [4,9,10]. Studies in mice have shown cell death through necrosis in several different tumor
types [4,5]. Normal cells and tissues have been shown to be less affected by calcium electroporation
than cancer cells and tissues [5,11]. Calcium electroporation has also been proven effective in two small
human clinical trials on cutaneous metastases, with a complete response rate of 66%, and recurrent head
and neck cancer, where one of the six included patients had a complete response [3,6]. Interestingly,
a patient with cutaneous metastases from malignant melanoma experienced a systemic immune response
with complete remission of treated as well as untreated tumors [12]. Induction of a systemic response
has been verified in an in vivo study where mice with a murine colorectal cancer tumor were treated
with calcium electroporation and then re-challenged with the same cancer cells and did not develop
new tumors [13].
A retrospective study from 2011, investigating the effect of treatment with a chemotherapeutic drug
(cisplatin) in combination with electroporation (electrochemotherapy) on equine sarcoids, showed very
low recurrence rates (1 of 194 treated sarcoids) [14]. However, due to restrictive regulations on the use
of chemotherapeutic drugs in veterinary medicine, the first study investigating calcium electroporation
treatment of equine sarcoids was initiated and recently published, showing the method´s safety and
short-term effects of the treatment [15]. Sixteen sarcoids in ten horses were treated with calcium
electroporation using surface electrodes, followed by surgical removal of sarcoids at 7, 14, and 21 days
after treatment. The treatment was well tolerated by all horses. The histological analysis showed
necrosis in 13 of 16 sarcoids, and, in nine of these, the fraction of necrosis was higher than 50%. Other
main changes in the sarcoids were hemorrhages in 14 of 16 sarcoids, ulceration in 13 of 16 sarcoids,
thrombosis in 13 of 16 sarcoids, and calcification in 11 of 16 sarcoids. Surrounding normal tissue
seemed less affected by the treatment than the tumor [15].
This study aimed to investigate the safety and long-term effects of calcium electroporation treatment of
equine sarcoids. We hypothesized that calcium electroporation would be safe and feasible for the treatment
of equine sarcoids, showing a long-term response rate comparable to the ones previously reported.
2. Materials and Methods
2.1. Study Design
Horses with one or more sarcoids were treated with calcium electroporation to evaluate the
long-term effect on the size of the sarcoid. A second treatment could be performed if the sarcoid was
not eliminated by the first treatment. The Danish Animal Experiments Inspectorate and The Danish
Veterinary and Food Administration (Ministry of Environment and Food of Denmark) were consulted
before the study regarding approval. These institutions deemed that since human clinical trials had
been completed [3,6], approval was not needed for the current equine study. The study used a similar
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treatment procedure as in previous human clinical trials [3,6]. All owners received written information
about the study and signed informed consent before treatment.
2.2. Selection of Animals
Healthy horses with at least one sarcoid able to undergo general anesthesia were included in
the study. Rectal temperature, cardiovascular, and respiratory status were examined before general
anesthesia, and animals with normal parameters were included in the study. Horses were included in
the study prospectively and consecutively.
2.3. Treatment
Horses were treated under general anesthesia. For premedication, horses were sedated with
acepromazine 0.03 mg/kg (Plegisil
®
), romifidine 0.05 mg/kg (Sedivet®), butorphanol 0.015 mg/kg
(Torbugesic®) i.v., and then ketamine 2 mg/kg (Aniketam®) and diazepam 0.05 mg/kg (Stesolid®) i.v.
for induction of the general anesthesia, and isoflouran 1.8%–2.2% (Attane®) for maintenance. The
horses were monitored during the procedure.
A highly experienced veterinarian clinically assessed the sarcoids (based on the history of the
horse, the appearance, and the location of the sarcoid) before inclusion in the study. All sarcoids
were measured and photographed using an iPhone 8 (Apple Inc., Cupertino, CA, USA), hairs around
the area were clipped, and standard surgical aseptic preparation was carried out before biopsies
were performed (using 8 mm biopsy punch), if assessed reasonable based on size and location of the
sarcoid, e.g., if more sarcoids were located close together, not all were biopsied. Sarcoid volume was
calculated as ab2pi/6, where a is the largest diameter, and b is the largest diameter perpendicular to
a [3,6]. However, this formula is less appropriate for very thin tumors, so, in cases of thin sarcoids, the
volume was calculated as abcpi/6, where a is the largest diameter, b is the largest diameter perpendicular
to a, and c is the actual thickness of the sarcoid.
Sarcoids were treated by injecting 220 millimolar (mM) calcium chloride solution (500 mM
calcium chloride diluted in physiological saline, equals 8.8 g/L calcium chloride) intratumorally,
followed by electroporation (Figure 1). Calcium was injected throughout the sarcoid using a 1 mL
29G BD Micro-Fine insulin syringe (Becton Dickinson, Wokingham Berkshire, England) in a volume
approximately equivalent to 50% of the sarcoid volume. The goal was to inject calcium in a volume
equivalent to 50% of the tumor volume; thus, if calcium solution was spilled during injection (e.g.,
through the biopsy hole), a similar volume was injected additionally. Immediately after the injection
of calcium, the sarcoid was electroporated with 8 pulses of 100 µs, 1000 V/cm, and 1 Hz using a
square-wave electroporator (Cliniporator EPS01; IGEA, Italy) and linear needle electrodes (20 mm in
length and 4 mm between electrodes; IGEA, Italy). The electrode was moved if needed to electroporate
the entire area. In the case of large sarcoids, the area was treated in sections to secure the presence of
high calcium concentration in the tissue when electroporating. Horses were treated twice if the sarcoid
was not eliminated after the first treatment and if the owners agreed to a second treatment. A second
treatment was performed four weeks or more after the first treatment, based on a recommendation
from treatments with electroporation in combination with a chemotherapeutic drug (in humans) [16,17]
and when feasible for the clinic and owner. Biopsies were only performed before treatment(s) in order
to not risk exacerbating tumor growth, which has previously been observed [1].
Horses could leave the clinic in their normal habitus a few hours after the procedure, yet some
horses stayed at the clinic overnight based on the owner’s decision.
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Figure 1. Images of the treatment. Horses were treated in general anesthesia (A and B). Calcium 
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2.4. Follow-up
Sarcoids were measured and photographed after the treatment(s), and the last follow-up, more
than 12 weeks after the first treatment (see Table 1), was performed when feasible for the clinic and
owner. The percentage change in the largest diameter was determined. Sarcoid areas, deemed as scar
tissue at follow-up, were set to a sarcoid diameter of 0 cm, representing a complete response.
Table 1. Overview of horses treated with calcium electroporation. Eight horses, six geldings and two
mares, aged 2–15 years, were treated. The horses had between 1 and 9 sarcoids placed in the head and
neck area, the extremities, and the ventral abdomen. The size of the sarcoids, the number of treatments,
and the length of follow-up for each of the horses are shown.
No. Sex Age(Years)
No. of
Sarcoids
Location of
Sarcoids
Size of
Sarcoids/
Largest
Diameter
(min - max)
Number of
Treatment(s)
(Weeks
Between
Treatments)
Follow-up (After
First Treatment)
1 gelding 11 years 3
Ventral
abdomen,
Extremities
2.4–3.5 cm 2(13 weeks) 17 weeks
2 gelding 15 years 5
H ad and
neck, Ventral
abdomen,
Extremities
4.4–8.7 cm 1
Withdrawn from
study due to
multiple large
mixed type sarcoids
3 gelding 4 years 3
Head and
neck, Ventral
ab omen
0.7–2.7 cm 2(4 weeks) 25 weeks
4 gelding 8 years 1 Ventralabdomen 3.0 cm 1 38 weeks
5 gelding 3 years 9
Head and
neck, Ventral
abdomen,
Extremities
0.9–5.0 cm 2(4 weeks) 26 weeks
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Table 1. Cont.
No. Sex Age(Years)
No. of
Sarcoids
Location of
Sarcoids
Size of
Sarcoids/
Largest
Diameter
(min - max)
Number of
Treatment(s)
(Weeks
Between
Treatments)
Follow-up (After
First Treatment)
6 gelding 2 years 3
Ventral
abdomen,
Extremities
3.5–4.5 cm 2(5 weeks) 22 weeks
7 mare 9 years 4 Head andneck 1.8–5.0 cm
2
(9 weeks) 32 weeks
8 mare 4 years 4
Ventral
abdomen,
Extremities
0.6–2.5 cm 2(4 weeks) 12 weeks
2.5. Histology
Biopsies were performed before treatment(s), immediately formalin-fixed and paraffin-embedded,
with subsequent sections of 3 µm stained with hematoxylin and eosin (HE). A pathologist verified
the sarcoid diagnosis and recorded the subtype (verrucous, fibroblastic, etc.) based on morphological
appearance, as well as the presence of necrosis, calcification, hyalinization, or ulceration.
3. Results
3.1. Included Horses and Sarcoids
Thirty-two sarcoids in eight horses (six geldings and two mares), aged 2–15 years, were treated
with calcium electroporation, as shown in Table 1. The number of sarcoids varied from 1–9 sarcoids
per horse and were situated on the head and neck, ventral abdomen, and extremities, as shown in
Tables 1 and 2. Six horses were treated twice with calcium electroporation with 4–13 weeks between
treatments. One horse (#4) was only treated once with calcium electroporation because the sarcoid was
completely eliminated after the first treatment (Figure 2A–C). Another horse (#2) was withdrawn from
the study after the first treatment and, therefore, only treated once due to multiple large mixed-type
sarcoids that were observed when the horse was in general anesthesia and hair clipped. The horse was
considered too severely affected and, therefore, withdrawn from the follow-up.
Table 2. Overview of sarcoids treated with calcium electroporation. The median number of sarcoids
per horse was 3.5, and they were situated mostly at the ventral abdomen followed by the extremities
and head and neck area. The size of the sarcoids—both volume and largest diameter—is shown. The
number of treatments, the injected volume of calcium, and the number of pulse series (8 pulses per
series) are also shown. The types of sarcoids treated were fibroblastic and verrucous.
No. of
Sarcoids
Per Horse
Median
(min, max)
Placement
of Sarcoids
Size of Sarcoids
Two
Treatments
CaCl2
Injected/mL
Mean
(min, max)
No. of Pulse
Series Mean
(min, max)
Histology
Volume/cm3
Mean
(min, max)
Largest
Diameter/cm
Mean
(min, max)
Type of
Sarcoids
3.5
(1, 9)
Head and
neck:
8 (25%)
Ventral
abdomen:
15 (47%)
Extremities:
9 (28%)
6.3 cm3
(0.1, 54.5)
2.9 cm
(0.6, 5.0)
6 of 8 horses
26 of 32
sarcoids
3.5 mL
(0.5, 9.0)
19
(4, 53)
52% (11/21)
fibroblastic
48% (10/21)
verrucous
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Figure 2. Complete response after calcium electroporation. Horse #4 (A–C). Pendulating, crusted, 
non-pigmented sarcoid on the ventral abdomen where the base of the sarcoid was treated once with 
calcium electroporation (A). Four days after the treatment, the sarcoid was starting to fall off (B) and 
completely gone 6 days after treatment (C). No regrowth was seen afterward (38 weeks after 
treatment). A biopsy was performed on the top of the sarcoid, verifying the diagnose. Horse #7 (D-F). 
Sarcoid on the eyelid was treated twice with calcium electroporation with 8 weeks between the 
treatments. (D) before the first treatment and (E) before the second treatment. Complete response was 
observed at follow-up 32 weeks after the first treatment (F) - notice the photo is from a caudo-lateral 
. rse 4 ). i , ,
ff
l gone 6 days after rea ment (C). No regr wth was seen afterward (38 eeks after tr atment).
A biopsy was performed on the top f t sarc id, verifying the diagnos . Horse #7 (D–F). Sarcoid
on the eyelid was treated twice with calcium electroporation with 8 weeks betwe n the treatments.
(D) before the first treatment and (E) before the second treatment. Complete response was observed t
follow-up 32 weeks after the first treatment (F) - notice the photo is from a caudo-lateral angle. A biopsy
was performed before the first and second treatment, with both biopsies verifying the diagnosis.
3.2. Safety
Calcium electroporation was well tolerated by all horses. As previously reported for electroporation-
based treatments, local muscle contractions occurred when electric pulses were applied [16]. No
complications during anesthesia nor calcium electroporation treatment were observed. Two horses that
developed a fever for 24–48 h duration and subcutaneous infection received intramuscular penicillin
procaine (25,000 IU/kg) and oral meloxicam (0.6 mg/kg) for five days. The remaining horses were
clinically unaffected except for local minor to moderate swelling of the treated area. The swelling of the
treatment area was observed in all horses after treatment and diminished within a few days. Needle
electrodes were used for the electroporation procedure and could be slightly difficult to pull out of the
sarcoid due to the firm tissue, pulling the tissue up and letting air enter the biopsy hole.
One of the horses (#1) was euthanized late in the follow-up period due to an accident unrelated to
the administered treatment or burden of sarcoids.
3.3. Effect
The size of the sarcoids was followed for 12–38 weeks after the first treatment (see Table 1).
Figure 3A illustrates the overall sarcoid response by the percentage size change (longest diameter) of
the sarcoid from the first treatment to the last follow-up.
Complete response was observed in six of 27 sarcoids (22%) located on the head and neck, as
well as the ventral abdomen, on four different horses. In four of these six lesions, no biopsies were
performed before any of the two treatments. In one of the sarcoids, which was pendulating with
a narrow base, a biopsy was only performed on the top of the sarcoid, while only the base of the
sarcoid was treated (Figure 2A–C); thus, no biopsy was performed in the treatment area. Biopsies were
performed in all other sarcoids, either before the first or second treatment or before both treatments.
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Figure 3. Sarcoid response to calcium electroporation. Percent change in the longest diameter at the
last follow-up (12–38 weeks after first treatment). The response of all sarcoids (A), showing 8 sarcoids
with progressive disease (above 20% increase; dotted line), 7 sarcoids with limited change (up to 30%
decrease but not above 20% increase), 6 sarcoids with partial response (more than 30% decrease; dotted
line), and 6 sarcoids with complete response (100% decrease). Data is also shown grouped by location
of sarcoid (B) and individual horse (C).
Partial response (more than 30% decrease of the longest diameter) was observed in six of 27
sarcoids (22%) located at the extremities, head and neck, as well as th ve tral abdomen, on four
different ors s. Limited changes in sarcoid size (up to 30% decrease but not above 20% increase)
observed in s ven sarcoids (26%) located o the extr mities and the ventral abdomen on four different
ho ses. Progressive dise e (more than 20% i crease) was observe in eight sarcoids (30%) located on
the extremities, head and neck, a well as the ventral abdo en, on five differ horses. In one of th
ho ses (#5), several n w smaller sarcoids we observed on the ventr l abdomen at follow-up 26 weeks
after the first treatm nt.
The response of the sarcoids did not se m related to the location of the sarcoid, as depicted in
Figu 3B. The arcoid response did ot depend on the horse as all horses with more than one sarcoid
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experienced response of some of the treated sarcoids and progression of other sarcoids (Figures 3C and
4). No relation between response and sarcoid size before treatment was observed (Figure 5).
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Figure 5. The sarcoid response related to sarcoid size. Percent change of sarcoid size (at the last
follow-up) after calcium electroporation treatment(s) on the y-axis related to the size of the sarcoid
before treatment on the x-axis. There does not seem to be a relation between sarcoid size and the
likelihood of treatment success with dots evenly spread across the graph.
3.4. Histology
Of the 27 sarcoids (32 treated sarcoids, excluding the five sarcoids treated on the horse that was
withdrawn from the study due to multiple large, mixed type sarcoids), 21 sarcoids were biopsied
before the first treatment. Of the six lesions not biopsied before the first treatment, two were biopsied
before the second treatment; thus, only four lesions were not biopsied. Histological analyses confirmed
the sarcoid diagnosis in all biopsied lesions. Analysis of the 21 sarcoids performed before the first
treatment showed that 11 (52%) were fibroblastic, and 10 (48%) were verrucous (Figure 6). In general,
few changes were observed in the biopsies likely due to the relatively long time span between the
Animals 2020, 10, 517 9 of 12
biopsies performed (time between the two treatments, ≥4 weeks). Necrosis was only observed in
one biopsy, and this was before the first treatment (70% necrosis). Ulceration was observed in five
sarcoids before the first treatment, and, of these, four also had ulceration before the second treatment.
In the other seven sarcoids, ulceration was observed before the second treatment. A small degree
of hyalinization was observed in a few sarcoids (seven before the first treatment, and two before
second treatment), and calcification was observed in five sarcoids after the first treatment (in biopsies
performed immediately before the second treatment). In two sarcoids on horse #5, hyperkeratosis
and pseudo-carcinomatous epithelial hyperplasia, respectively, were observed. Only limited changes
in sarcoid size were shown in these sarcoids. No dependency between sarcoid response and type,
ulceration, hyalinization, nor calcification was observed.
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4. Discussion
Sarcoids are common equine skin tumors with many treatment options but no consistently effective
treatments. Thus, viable treatment options, where practical and financial aspects are taken into account,
are needed. Calciu electroporation is a simple and inexpensive local tumor treatment, proven safe
and efficient in human clinical trials on patients ith cutaneous metastases from breast cancer and
malignant melanoma [3,18], as well as on the recurrent and mucosal head and neck cancer [6]. In a
recent study, calcium electroporation was tested on equine sarcoids, where short-term effects of the
treatment were observed with calcium electroporation performed preoperatively [15]. In this study, we
investigated the safety as well as the long-term effects of calcium electroporation treatment of sarcoids.
Like the clinical trials on humans and the recent equine study, we observed that calcium
electroporation is safe and feasible for local treat ent of equine sarcoids. Overall, 44% (12/27) of
the treated sarcoids responded to the treatment, with more than a 30% decrease in the longest
diameter. In the study, investigating short-term effects, nine of 16 sarcoids (56%) treated with calcium
electroporation showed more than 50% necrosis 7–21 days after treatment [15]. This was slightly higher
than the long-term response we observed, which was likely due to regrowth in some of the sarcoids
over time. Sarcoid location, sarcoid type (fibroblastic or verrucous), and sarcoid size before treatment
seemed unrelated to treatment response; however, further studies are needed. The correlation between
short-term response and sarcoid size before treatment has been previously observed [15].
None of the horses showed a response in all treated sarcoids (if more than one sarcoid was
treated), indicating that the response was based on individual parameters of each sarcoid and not
host-related factors. Furthermore, this indicated that no systemic immune response was induced,
previously seen in a patient with cutaneous metastases from malignant melanoma treated with calcium
electroporation [12], as well as a mouse study investigating systemic immune response after calcium
electroporation [13]. Further investigations of the induction of a systemic immune response using
calcium electroporation would be of great interest for treatments in the human clinical setting, as well
as the veterinary setting.
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Complete response was observed in 22% (6/27) of the treated sarcoids, which was lower than
after surgical removal, where recurrence was reported in 50%–65% of sarcoids [19]. Interestingly,
in four of the six lesions with complete response, no biopsies had been performed in the treatment
area. Leakage of calcium through the biopsy hole might have reduced the efficacy of the treatment
despite the injection of additional calcium. Furthermore, biopsy-induced trauma or irritation is known
to exacerbate the sarcoid and induce growth [20], which might also reduce the efficacy of calcium
electroporation, although the treatment itself induces some trauma (injection and needle electrodes).
However, better response rates were observed in non-biopsied lesions, indicating that trauma induced
by the treatment itself did not exacerbate the sarcoids. It would be very interesting to investigate the
response rate of calcium electroporation on sarcoids without concurrent biopsies in future studies.
Limitations
This study showed that calcium electroporation of sarcoids is feasible; however, it can be difficult
to disperse calcium in the tough tissue. We, therefore, chose to use insulin syringes to ensure that the
needle and syringe stayed together under high injection pressure. Due to the tough tissue, which
might result in limited diffusion, we injected calcium in a grid pattern all over the sarcoid to ensure
the presence of calcium throughout the sarcoid tissue. Despite the firmness of the tissue, we did not
experience any difficulties placing the needle electrode in the tissue, nor the needles becoming blunt
after use on several sarcoids (on the same horse). However, sometimes, we had trouble with the
generator turning off due to the current in the tissue being too high (above 13 A; note the generator
used was an older model). This might happen in some tissue types, but generators that generate
higher currents are available, which could potentially solve this problem. In this study, we used needle
electrodes, which, sometimes, were slightly difficult to remove, elevating the tissue, and letting air
enter through the biopsy hole. This could easily be avoided by pushing the tissue down while pulling
the electrode out. Other electrodes could also be used for the treatment. In the previous sarcoid study,
surface electrodes were used, which treated 2–3 mm of the sarcoid at each treatment, whereas needle
electrodes treat a deeper area of the sarcoid. The effect of the treatments using different electrodes
cannot be compared since the endpoints in the two studies are different, but it is important to note the
different technical solutions being employed.
Previous treatments of the sarcoids, in this study, were not registered. This might affect the
response rate of the sarcoid since it has been shown that recurrence following treatment of sarcoids is
associated with exacerbation [20]. Thus, response rates might be higher in previously untreated sarcoids.
Registration of previous treatments might be interesting for future studies with calcium electroporation
of sarcoids. In this study, we chose also to include four lesions that were not biopsy-verified, although
complete certain identification of sarcoids requires histopathological analysis. However, given the
experience of the veterinarian, and the fact that all biopsied lesions were histologically verified as
sarcoids, we found it credible that the clinical diagnosis of sarcoid of these four lesions was also correct.
The evaluation of a possible new treatment for sarcoids is, of course, based on the response rate, as
well as the cost of treatment. Calcium electroporation on horses is performed in general anesthesia and
requires electroporation equipment, generator, and electrodes. Although electroporation equipment
for veterinary use is reasonably priced, the cost of the treatment is higher than surgical removal.
Furthermore, calcium electroporation may not be the first treatment choice for sarcoids based on these
few cases since the response rate is slightly lower than after surgical removal. The response rate, in this
study, was also lower than the response shown in a retrospective study of electrochemotherapy on
equine sarcoids [14]; however, the use of chemotherapeutic agents requires higher safety standards and
expensive handling of biological hazard waste. A great advantage of calcium electroporation treatment
is, nevertheless, that it is possible in areas where surgical removal is challenging, such as sarcoids placed
on the eyelid. In this study, sarcoids located around the eye on horse #7 that could not be surgically
removed without removing the eye as well were treated with calcium electroporation with complete
response. Thus, calcium electroporation may be a suitable treatment option for inoperable sarcoids.
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5. Conclusions
This study confirmed that calcium electroporation is safe and feasible for the treatment of equine
sarcoids, including inoperable sarcoids. The study is the first to investigate the long-term response rate
of calcium electroporation treatment of sarcoids, and it showed 22% (6/27) complete response and 22%
(6/27) partial response (defined as more than 30% decrease of the longest diameter). The response of
the sarcoids was not related to location, sarcoid type, nor size. Non-biopsied lesions showed complete
response after calcium electroporation. Calcium electroporation is, based on the limited results of
this study, currently not assessed as a suitable alternative treatment over surgical removal of sarcoids;
however, calcium electroporation is deemed safe and feasible, and we observed a very good response
rate in some of the sarcoids.
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